**SUPPLEMENTARY DATA**

**Table 1 of the supplementary data**

Contraindication to long term oral anticoagulation (OAC)

| Absolute contraindication | - Severe uncorrectable anemia (eg, thalassemia) <br> - Prior life-threatening bleeding <br> - Multiple significant falls <br> - Prior ICB or OAC <br> - Prior SAH – known cerebral aneurysm <br> - Untreatable HHT |
|---|---|
| Relative contraindication | - Noncompliance with OAC <br> - Malignancy <br> - Chronic end-stage renal disease <br> - Amyloid <br> - Chronic bacterial endocarditis <br> - High-risk occupation (eg, active duty military, fireman) <br> - Failure of prior OAC |

HHT, hereditary hemorrhagic telangiectasia; ICH, intracerebral bleeding; SAH, subarachnoid bleeding.

**Table 2 of the supplementary data**

Baseline, Procedural Characteristics, and In-Hospital Outcomes, Overall and According to Early and Late Readmissions Following LAAC

| Variables | Early readmission (n = 46) | Late readmission (n = 211) | P |
|---|---|---|---|
| **Baseline characteristics** | | | |
| *Age, y* | 78.4 ± 9.1 | 77.0 ± 7.7 | .013 |
| *Female sex* | 15 (32.6) | 69 (32.7) | .321 |
| *BMI, kg/m$^2$* | 26.3 ± 4.3 | 26.7 ± 4.8 | .028 |
| *Hypertension* | 41 (89.1) | 190 (90.1) | .273 |
| *Diabetes mellitus* | 17 (36.9) | 91 (43.1) | .008 |
| *Current smoking* | 9 (19.6) | 42 (20.2) | .153 |
| *Chronic renal disease, eGFR < 60 mL/min/1.73m$^2$* | 18 (39.1) | 113 (53.6) | < .001 |
| *Type of atrial arrhythmia* | | | |
| Paroxysmal | 2 (4.4) | 18 (8.5) | .470 |
| Chronic | 25 (54.4) | 124 (58.8) | |
| *Previous cerebral events* | | | |
| Ischemic stroke | 10 (21.7) | 72 (34.1) | .071 |
| Hemorrhagic stroke | 6 (13.0) | 41 (19.4) | .003 |
| TIA | 1 (2.2) | 17 (8.1) | .371 |
| *Coronary artery disease* | 20 (43.5) | 76 (36.0) | .207 |
| *Peripheral artery disease* | 14 (30.4) | 67 (31.8) | .007 |
| *Heart failure* | 11 (23.9) | 85 (40.3) | < .001 |
| *Previous bleeding* | 41 (89.1) | 185 (87.7) | .098 |
| Previous gastrointestinal bleeding | 29 (63.0) | 99 (48.3) | < .001 |
| Previous Intracranial bleeding | 8 (17.4) | 50 (24.4) | < .001 |
| *Oral anticoagulation contraindication* | | | |
| None | 7 (15.2) | 21 (9.9) | .009 |
| Relative | 15 (32.6) | 80 (37.9) | |
| Absolute | 24 (52.2) | 110 (52.1) | |
| *CHA$_2$DS$_2$-VASc* | 4.22 ± 1.19 | 4.62 ± 1.41 | .015 |
| *HAS-BLED* | 3.72 ± 0.86 | 4.00 ± 1.01 | < .001 |
| *Antithrombotic treatment at discharge* | | | |
| *SAPT* | 13 (28.3) | 56 (26.5) | .969 |

| | | | |
|---|---|---|---|
| *DAPT* | 27 (58.7) | 98 (46.5) | .005 |
| *OAC* | 6 (13.0) | 51 (24.2) | .009 |
| *OAC + SAPT* | 0 (0) | 4 (1.9) | .021 |
| **Procedural characteristics** | | | |
| *Prothesis type* | | | |
| Amplatzer (cardiac plug or amulet) | 30 (65.2) | 149 (70.6) | .716 |
| Watchman (FLX or 2.5) | 13 (28.3) | 52 (24.6) | |
| Other | 3 (6.5) | 10 (4.7) | |
| *Procedural success* | 46 (100) | 211 (100) | .706 |
| *Complete occlusion* | 45 (97.8) | 195 (92.9) | .457 |
| *Prothesis embolization* | 1 (2.2) | 1 (0.5) | .007 |

BMI, body mass index; TIA, transient ischemic attack; SAPT, single antiplatelet therapy; DAPT, dual antiplatelet therapy; OAC, oral anticoagulant.

The data are expressed as No. (%) or mean ± standard deviation.